Clinical Trial Update: The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 12 months of denosumab on bone density in prevalent kidney transplant recipients; the study was terminated but results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Renal Osteodystrophy

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Thomas Nickolas, MD MS | Conditions: Osteoporosis, Renal Osteodystrophy | Phase 2 | Status: TERMINATED | Results posted: 2024-07-25